Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter-Op Settlement Stays $15.5 Mil. In Damages; State Plaintiffs Appeal

This article was originally published in The Gray Sheet

Executive Summary

Sulzer Medica is relying on an anticipated class settlement to impose a seven-year freeze on hip and knee revision damages already being awarded at the state court level.

You may also be interested in...



Centerpulse/Sulzer Cuts Settlement Opt-Outs To 87, Sidesteps Bankruptcy

Centerpulse plans to "aggressively defend" in court any outstanding claims related to its Inter-Op hip implant and Natural Knee II recalls that were not part of a class settlement, but the firm has not ruled out the possibility of settling those claims out of court

Centerpulse/Sulzer Cuts Settlement Opt-Outs To 87, Sidesteps Bankruptcy

Centerpulse plans to "aggressively defend" in court any outstanding claims related to its Inter-Op hip implant and Natural Knee II recalls that were not part of a class settlement, but the firm has not ruled out the possibility of settling those claims out of court

Sulzer Hip Recall Settlement Exceeds $1 Bil., Doubles Patient Damages

Sulzer Medica is in negotiations with CMS to broker a global settlement for Medicare patients affected by the firm's hip and knee implant recall

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel